3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Completed
7
Unknown
3
Terminated
2
Recruiting
2
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Penile Neoplasms
1
Non-Small Cell Lung Cancer With HER2- Mutations
1
Melanoma
1
Male Urogenital Diseases
1
Lung Neoplasms
1
First-line Advanced NSCLC Patients
1
Esophageal Squamous Cell Carcinoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
115
Carboplatin
103
Pemetrexed
90
Cisplatin
58
Paclitaxel
47
osimertinib
41
Drug Therapy
40
Nivolumab
39
Docetaxel
35
Specimen Handling
33
Magnetic Resonance Spectroscopy
28
Bevacizumab
26
durvalumab
23
Gemcitabine
22
cemiplimab
21
Radiotherapy
20
130-nm albumin-bound paclitaxel
20
Radiosurgery
19
tislelizumab
18
atezolizumab
17
aflutinib
15
Cetuximab
15
Immunotherapy
14
Immune Checkpoint Inhibitors
14
Platinum Compounds
13
Ipilimumab
13
Biopsy
12
Standard of Care
11
Surgical Procedures, Operative
10
Injections
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Non-Small-Cell Lung
×
CP protocol
×
Clear all
NCT05061550
2026-05-22
NeoCOAST-2
AstraZeneca
Phase 2
Recruiting
630 enrolled
NCT07365319
2026-05-20
TeLuRide-008
Eikon Therapeutics
Phase 2/3
Recruiting
750 enrolled